Quantinuum Inc (QNT)

NASDAQInformation TechnologyComputer HardwareSnapshot 2026-10-23

$36.50+1.67%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Quantinuum Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	8.83M
EPS	—	-0.393
Annual ending 2026-12-31
Revenue	—	30.08M
EPS	—	-1.67
Annual ending 2027-12-31
Revenue	—	61.18M
EPS	—	-1.65

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce operating losses	A supporting condition in Quantinuum Inc's published investment case. The stated target is operating losses below $500 million.	Intact	operating losses exceed $500 million	Operating income: $-555.026M FY2026-Q2; GAAP. Published target: operating losses below $500 million. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 13, 2026-555,026,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: afe9f9be-e413-463d-a434-11b4f3ab031b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Quantinuum reported an operating loss of $555 million and net loss of $65 million in 2026-Q2, underscoring the priority to improve financial performance and reduce losses. As this is the first quarter with this explicit focus, the trajectory is at an early stage with significant losses persisting. Delivery assessment Oct 24, 2026
Leverage $100 million CHIPS Act award for R&D	Quantinuum is advancing quantum computing with a $100 million CHIPS Act award.	Intact	fails to secure the full $100 million funding	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q3. Quantinuum finalized a $100 million CHIPS Act award to support R&D and U.S. manufacturing of trapped-ion quantum computers. This federal funding aims to strengthen domestic supply chains and scale fault-tolerant systems. As this is a new priority, no prior quarters exist for comparison; the trajectory is at initial delivery stage. Delivery assessment Oct 24, 2026
Accelerate hybrid quantum compute adoption via partnerships	Strategic partnerships with companies like Oracle enhance growth potential.	Intact	fails to secure new partnerships	2 partnerships vs >=2 target Oracle partnership announced Aug 2026; Aramco MoU signed Sep 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management announced a strategic partnership with Oracle to accelerate hybrid quantum compute adoption on Oracle Cloud Infrastructure. No prior quarters mention this priority, so trajectory assessment is limited to initial announcement. Delivery assessment Oct 24, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.65

$-1.65 → $-1.65 · observed estimates

FY2027 revenue$0.06B

$0.06B → $0.06B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-07	$-1.65	$61,150,000	7 / 8
2026-09-08	$-1.65	$61,150,000	7 / 8
2026-09-09	$-1.65	$61,150,000	7 / 8
2026-09-10	$-1.65	$61,150,000	7 / 8
2026-09-11	$-1.65	$61,150,000	7 / 8
2026-09-12	$-1.65	$61,150,000	7 / 8
2026-09-13	$-1.65	$61,150,000	7 / 8
2026-09-14	$-1.65	$61,150,000	7 / 8
2026-09-15	$-1.65	$61,150,000	7 / 8
2026-09-16	$-1.65	$61,150,000	7 / 8
2026-09-17	$-1.65	$61,150,000	7 / 8
2026-09-18	$-1.65	$61,150,000	7 / 8
2026-09-19	$-1.65	$61,150,000	7 / 8
2026-09-20	$-1.65	$61,150,000	7 / 8
2026-09-21	$-1.65	$61,150,000	7 / 8
2026-09-22	$-1.65	$61,150,000	7 / 8
2026-09-23	$-1.65	$61,150,000	7 / 8
2026-09-24	$-1.65	$61,150,000	7 / 8
2026-09-25	$-1.65	$61,150,000	7 / 8
2026-09-26	$-1.65	$61,150,000	7 / 8
2026-09-27	$-1.65	$61,150,000	7 / 8
2026-09-28	$-1.65	$61,150,000	7 / 8
2026-09-29	$-1.65	$61,150,000	7 / 8
2026-09-30	$-1.65	$61,150,000	7 / 8
2026-10-01	$-1.65	$61,150,000	7 / 8
2026-10-02	$-1.65	$61,150,000	7 / 8
2026-10-03	$-1.65	$61,150,000	7 / 8
2026-10-04	$-1.65	$61,150,000	7 / 8
2026-10-05	$-1.65	$61,150,000	7 / 8
2026-10-06	$-1.65	$61,150,000	7 / 8
2026-10-07	$-1.65	$61,150,000	7 / 8
2026-10-08	$-1.65	$61,150,000	7 / 8
2026-10-09	$-1.65	$61,150,000	7 / 8
2026-10-10	$-1.65	$61,150,000	7 / 8
2026-10-11	$-1.65	$61,150,000	7 / 8
2026-10-12	$-1.65	$61,150,000	7 / 8
2026-10-13	$-1.65	$61,150,000	7 / 8
2026-10-14	$-1.65	$61,150,000	7 / 8
2026-10-15	$-1.65	$61,150,000	7 / 8
2026-10-16	$-1.65	$61,150,000	7 / 8
2026-10-17	$-1.65	$61,150,000	7 / 8
2026-10-18	$-1.65	$61,180,000	7 / 9
2026-10-19	$-1.65	$61,180,000	7 / 9
2026-10-20	$-1.65	$61,180,000	7 / 9
2026-10-21	$-1.65	$61,180,000	7 / 9
2026-10-22	$-1.65	$61,180,000	7 / 9
2026-10-23	$-1.65	$61,180,000	7 / 9
2026-10-24	$-1.65	$61,180,000	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-07-01	12	1
2026-08-01	12	1
2026-09-01	12	1
2026-10-01	13	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 15

$62.00New observation · no comparable prior

$0$34.10$68.20

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce operating lossesOperating income: $-555.026M
Leverage $100 million CHIPS Act award for R&DDirect metric needs a verified mapping

Next proof point

Nov 10, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.4%Typical daily move · historical

Downside history

-60.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Quantinuum Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

QNT is a speculative growth business tied to quantum computing, with a long-term thesis that depends on turning research and partnerships into broader adoption. The thesis state is insufficient because the evidence does not provide enough recent financial history, and overall confidence is low.

What's priced into Quantinuum Inc

The snapshot provides no valuation measures or clear account of what the market expects, so valuation cannot be assessed. Fragility indicators are low, but that does not establish whether expectations are modest or demanding.

What the fundamentals likely do

Near-term, management has new initiatives: a $100 million CHIPS Act award for research and U.S. manufacturing, plus an Oracle Cloud partnership. Both are at an early stage, while the reported operating and net losses show that financial improvement remains unresolved; recent earnings misses are another risk.

What Quantinuum Inc hinges on

Over the next one to three years, the thesis hinges on whether the funding supports manufacturing progress and the Oracle partnership helps expand hybrid quantum adoption. Near-term sector conditions may also matter: rate cuts and strong results from technology bellwethers could support the sector backdrop, while weaker results could remove that support.